REG - Cellbxhealth PLC - PDMR Dealing and ESOT Share Purchase

CellbxhealthAnnouncement

19/12/2025 18:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251219:nRSS3647Ma&default-theme=true

RNS Number : 3647M  Cellbxhealth PLC  19 December 2025

CELLBXHEALTH plc ("the Company")

DIRECTOR/PDMR SHAREHOLDING AND ESOT SHARE PURCHASE

Guildford, UK - 19 December 2025 - CELLBXHEALTH plc (AIM:CLBX), a leader in
circulating tumour cell (CTC) intelligence, with tests and services supporting
research, drug development and clinical oncology,  announces that, following
the Oversubscribed Placing and Subscription announced on the 25 November 2025,
Executive Chairman, Jan Groen and Chief Executive Officer Peter Collins each
acquired 5,000,000 Ordinary Shares in the Company. In addition, Sinead
Armstrong, Finance Director acquired 2,500,000 Ordinary Shares in the
Company.  All shares were purchased at a price of 1.0 pence, being the
Placing Price.

Following the transaction, Dr Groen's and Mr Collins' aggregate direct and
indirect ultimate beneficial interest in the Company's Ordinary Shares is
5,000,000 representing approximately 0.4% of the Company's currently issued
share capital, Mrs Armstrong's aggregate direct and indirect ultimate
beneficial interest in the Company's Ordinary Shares is 2,596,056 representing
approximately 0.2% of the Company's currently issued share capital.

Employee Share Ownership Trust Share Purchase

Furthermore, the Company announces that Zedra Trust Company (Guernsey) Ltd,
acting as trustee of the ANGLE Employee Share Ownership Trust (the "ESOT"),
purchased, earlier today, a total of 2,886,742 ordinary shares in the Company
at a price of 1.1p each.

 The shares will be held in the ESOT, which is a discretionary trust for the
benefit of the Company's employees and will ultimately be used to satisfy
share awards and options granted under the Company's various share incentive
arrangements.

The ESOT may be used to assist in meeting the obligations under employee
remuneration schemes with Executive Directors and Persons Discharging
Managerial Responsibility of the Company, together with other employees, as
potential beneficiaries and are therefore treated as having an interest in
some of those shares and the dealings thereof.

 Immediately following settlement of the above transaction, the ESOT will
hold 3,000,000 ordinary shares ("ESOT Shares") representing 0.3% of the
Company's issued share capital.

 The Company's issued share capital as at 19 December 2025 consists of
1,139,402,658 ordinary shares of 0.05 pence each with voting rights. The
Company does not hold any shares in treasury and has waived its right to
exercise its voting rights and to receive dividends in respect of the EBT
Shares. Therefore, the total number of voting rights is 1,136,402,658.

Unless otherwise defined, all capitalised terms used but not defined in this
announcement shall have the meaning given to them in the Announcement on 24
November 2025.

For further information:

 

 CelLBxHealth plc                                +44 (0) 1483 343434
 Peter Collins, Chief Executive Officer           investor@cellbxhealth.com

 Jan Groen, Executive Chairman

 Cavendish (NOMAD and Broker)

 Geoff Nash / Isaac Hooper (Corporate Finance)   +44 (0) 20 7220 0500

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)
  FTI Consulting

 Simon Conway, Ciara Martin, Sam Purewal         +44 (0) 203 727 1000

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014) as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018, as amended. Upon the publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain.

Notes for editors

About CelLBxHealth plc

CelLBxHealth plc is a precision CTC intelligence company specialising in
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology. Its patent-protected Parsortix® platform
harvests CTCs from blood and can be integrated with existing laboratory
instruments for comprehensive downstream analysis - including whole-cell
imaging, proteomic profiling and full genomic workflows.

Commercial activities centre on (1) Product Sales: Accelerating Parsortix
platform adoption and consumable sales through CROs and clinical lab
partnerships. (2) Laboratory services: Clinical trial support and assay
development (3) Lab Developed Tests (LDTs): Strategic partnerships combined
with a focused in-house development programme.

 The product portfolio comprises the Parsortix® platform with associated
consumables and assays. Laboratory services are delivered from CelLBxHealth's
GCLP certified UK laboratory, providing bespoke clinical-trial support and
assay development.

For more information, visit https://cellbxhealth.com/
(https://cellbxhealth.com/) .

The Company's LEI is 213800BY11K6W3NMS374

 This announcement should be read in its entirety. In particular, the
information in the "Important Notices" section of the announcement should be
read and understood.

Notification and public disclosure of transactions by Persons Discharging
Managerial Responsibilities ("PDMR") and persons closely associated with them
("PCA")

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail in respect of the transaction
as described above.

 

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         a)   Jan Groen

                                                                  b)   Peter Collins

                                                                  c)   Sinéad Armstrong
 2   Reason for the notification
 a)  Position/status                                              a)   Jan Groen (Chairman)

                                                                  b)   Peter Collins (CEO)

                                                                  c)   Sinéad Armstrong (FD)

 b)  Initial notification /Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         CelLBxHealth Plc
 b)  LEI                                                          213800BY11K6W3NMS374
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 0.05 pence value each

     Identification code                                          GB0034330679

 b)  Nature of the transaction

                                                                  a)   Jan Groen - Purchased 5,000,000 Ordinary Shares

                                                                  b)   Peter Collins - Purchased 5,000,000 Ordinary Shares

                                                                  c)   Sinead Armstrong - Purchased 2,500,000 Ordinary Shares

 c)  Price(s) and volume(s)
                                                                                    Price(s)          Volume(s)
                                                                                    a)   1p           a)   5,000,000

                                                                                    b)   1p           b)   5,000,000

                                                                                    c)   1p           c)   2,500,000

 d)  Aggregated information

     - Aggregated volume                                          n/a, each a single transaction

     - Price                                                      n/a, each a single transaction

 e)  Date of the transaction                                      18 December 2025
 f)  Place of the transaction                                     AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFMFWUEISELE



            Copyright 2019 Regulatory News Service, all rights reserved